{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Xiang X"],"pubmed_abstract":["<h4>Background</h4>There is ongoing debate about the safety and efficacy of epicutaneous immunotherapy (EPIT) in treating food allergies. The systematic review and meta-analysis aimed to evaluate the safety and efficacy of EPIT.<h4>Methods</h4>We systematically searched international trial registers (ClinicalTrials.gov), PubMed, Embase, the Cochrane Central of Controlled Trials (CENTRAL), and Web of Science from the inception of the database until June 25, 2023. Two authors independently screened potential studies based on the following criteria: food allergy, epidermal immunotherapy, and randomized controlled trials(RCTs). The risk-of-bias assessment was performed using the Cochrane risk-of-bias 2 (ROB 2) tool. The primary outcomes included desensitization, local adverse events, systemic "],"journal":["Systematic reviews"],"pagination":["4"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11697646"],"repository":["biostudies-literature"],"pubmed_title":["Epicutaneous immunotherapy for food allergy: a systematic review and meta-analysis."],"pmcid":["PMC11697646"],"pubmed_authors":["Li X","Hu J","Gao Y","Cui X","Xiang X","Sachu R","Chen S","Gao C","Niu H"],"additional_accession":[]},"is_claimable":false,"name":"Epicutaneous immunotherapy for food allergy: a systematic review and meta-analysis.","description":"<h4>Background</h4>There is ongoing debate about the safety and efficacy of epicutaneous immunotherapy (EPIT) in treating food allergies. The systematic review and meta-analysis aimed to evaluate the safety and efficacy of EPIT.<h4>Methods</h4>We systematically searched international trial registers (ClinicalTrials.gov), PubMed, Embase, the Cochrane Central of Controlled Trials (CENTRAL), and Web of Science from the inception of the database until June 25, 2023. Two authors independently screened potential studies based on the following criteria: food allergy, epidermal immunotherapy, and randomized controlled trials(RCTs). The risk-of-bias assessment was performed using the Cochrane risk-of-bias 2 (ROB 2) tool. The primary outcomes included desensitization, local adverse events, systemic ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-22T09:01:13.4Z","creation":"2025-04-05T22:50:24.65Z"},"accession":"S-EPMC11697646","cross_references":{"pubmed":["39748365"],"doi":["10.1186/s13643-024-02727-6"]}}